These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 2173410

  • 21. Vimentin--a new prognostic parameter in breast carcinoma?
    Raymond WA, Leong AS.
    J Pathol; 1989 Jun; 158(2):107-14. PubMed ID: 2547048
    [Abstract] [Full Text] [Related]

  • 22. Ductal carcinoma of the breast. An analysis of proportions of intraductal and invasive components.
    Matsukuma A, Enjoji M, Toyoshima S.
    Pathol Res Pract; 1991 Jan; 187(1):62-7. PubMed ID: 1851298
    [Abstract] [Full Text] [Related]

  • 23. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma.
    Jaffer S, Orta L, Sunkara S, Sabo E, Burstein DE.
    Hum Pathol; 2007 Jun; 38(6):864-70. PubMed ID: 17350670
    [Abstract] [Full Text] [Related]

  • 24. Cathepsin D in invasive ductal NOS, medullary, lobular and mucinous breast carcinoma. An immunohistochemical study.
    Bedner E, Harezga B, Osborn M, Domagała W.
    Pol J Pathol; 1995 Jun; 46(1):11-5. PubMed ID: 7780691
    [Abstract] [Full Text] [Related]

  • 25. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
    Palacios J, Benito N, Pizarro A, Suárez A, Espada J, Cano A, Gamallo C.
    Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
    [Abstract] [Full Text] [Related]

  • 26. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
    Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu SI.
    Ann Clin Lab Sci; 2006 Mar; 36(1):16-22. PubMed ID: 16501232
    [Abstract] [Full Text] [Related]

  • 27. Keratin 19 in paraffin sections of medullary carcinoma and other benign and malignant breast lesions.
    Dalal P, Shousha S.
    Mod Pathol; 1995 May; 8(4):413-6. PubMed ID: 7567941
    [Abstract] [Full Text] [Related]

  • 28. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
    Kalogeraki A, Garbagnati F, Santinami M, Zoras O.
    In Vivo; 2002 May; 16(2):141-4. PubMed ID: 12073773
    [Abstract] [Full Text] [Related]

  • 29. Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma.
    Pilichowska M, Kimura N, Fujiwara H, Nagura H.
    Mod Pathol; 1997 Oct; 10(10):969-75. PubMed ID: 9346175
    [Abstract] [Full Text] [Related]

  • 30. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast.
    Wetzels RH, Holland R, van Haelst UJ, Lane EB, Leigh IM, Ramaekers FC.
    Am J Pathol; 1989 Mar; 134(3):571-9. PubMed ID: 2466404
    [Abstract] [Full Text] [Related]

  • 31. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
    Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R.
    Oncogene; 1998 Dec 17; 17(24):3169-76. PubMed ID: 9872332
    [Abstract] [Full Text] [Related]

  • 32. Vimentin expression in benign and malignant breast epithelium.
    Heatley M, Whiteside C, Maxwell P, Toner P.
    J Clin Pathol; 1993 May 17; 46(5):441-5. PubMed ID: 7686566
    [Abstract] [Full Text] [Related]

  • 33. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang P.
    Hum Pathol; 2008 Mar 17; 39(3):386-92. PubMed ID: 18187183
    [Abstract] [Full Text] [Related]

  • 34. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Mar 17; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 35. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER, Tubbs RR, Myles JL, Procop GW.
    Am J Clin Pathol; 2002 Jun 17; 117(6):916-21. PubMed ID: 12047143
    [Abstract] [Full Text] [Related]

  • 36. Classification and grading of invasive breast carcinoma.
    Elston CW.
    Verh Dtsch Ges Pathol; 2005 Jun 17; 89():35-44. PubMed ID: 18035670
    [Abstract] [Full Text] [Related]

  • 37. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
    Bratthauer GL, Saenger JS, Strauss BL.
    Histopathology; 2005 Dec 17; 47(6):611-6. PubMed ID: 16324199
    [Abstract] [Full Text] [Related]

  • 38. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast.
    Geradts J, Ingram CD.
    Mod Pathol; 2000 Sep 17; 13(9):945-53. PubMed ID: 11007034
    [Abstract] [Full Text] [Related]

  • 39. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena.
    Kopans DB, Rafferty E, Georgian-Smith D, Yeh E, D'Alessandro H, Moore R, Hughes K, Halpern E.
    Cancer; 2003 Jun 15; 97(12):2951-9. PubMed ID: 12784329
    [Abstract] [Full Text] [Related]

  • 40. Vimentin expression in 98 breast cancers with medullary features and its prognostic significance.
    Holck S, Pedersen L, Schiødt T, Zedeler K, Mouridsen H.
    Virchows Arch A Pathol Anat Histopathol; 1993 Jun 15; 422(6):475-9. PubMed ID: 8392769
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.